Autopsy report · NCT00312442

Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“STEBA decided to develop WST11 that is soluble in aqueous solutions. The property of WST 11 make it safer and better candidate for therapeutic applications.”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 3 years 7 months before it stopped.
16 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 2, Phase 3
Sponsor: STEBA France
Sponsor type: Industry
Conditions: Prostate Cancer
Interventions: Treatment with WST09 Vascular Photodynamic therapy
Participants: 16
Sites: 1
Countries: Canada

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.